Related Experiment Video
Updated: Oct 13, 2025
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy:
Pascal Hänggi1, Butrint Aliu2, Kea Martin2
1From the Polyneuron Pharmaceuticals AG (P.H.,K.M.,R.H.), Basel; Molecular Pharmacy (P.H.,B.A.,R.H.), Pharmacenter, University of Basel; and Clinic of Neurology (A.J.S.), Department of Medicine, University Hospital Basel, University of Basel, Switzerland. pascalrhaenggi@gmail.com.
A reduction in serum anti-myelin-associated glycoprotein (MAG) autoantibodies correlates with improved clinical response in patients undergoing immunotherapy for anti-MAG neuropathy. A sustained decrease of 50% or more in antibody levels indicates a positive therapeutic outcome.
Area of Science:
- Neurology
- Immunology
- Clinical Medicine
Background:
- Anti-myelin-associated glycoprotein (MAG) neuropathy is an autoimmune disorder.
- The relationship between anti-MAG autoantibody levels and treatment response requires further clarification.
Purpose of the Study:
- To investigate the association between changes in serum anti-MAG autoantibodies and clinical response to immunotherapy in patients with anti-MAG neuropathy.
Main Methods:
- A retrospective analysis of 50 studies (410 patients) identified via Medline search.
- Evaluation of anti-MAG immunoglobulin M (IgM) autoantibody titers and clinical outcomes during immunotherapy.
- Categorization of patients into responders, nonresponders, or acute deteriorating based on clinical response.
Main Results:
- Forty studies (303 patients) supported the hypothesis: responders showed reduced anti-MAG antibody levels, while nonresponders did not.
- Six studies partially supported the hypothesis, and four studies did not provide support.
- A sustained reduction of at least 50% in anti-MAG IgM titers was associated with clinical improvement.
Conclusions:
- The study confirms that a reduction in serum anti-MAG IgM antibodies is linked to clinical response in immunotherapy for anti-MAG neuropathy.
- A significant decrease in anti-MAG antibody levels can serve as a predictive marker for therapeutic efficacy.
